retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide, a GIP, and receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 trial conducted in the USA Why does GLP‐1 agonist combined
Description
doi: 10.1074/jbc.M111.276808

doi: 10.1001/JAMAINTERNMED.2022.0338 114 McCleanPLGaultVAHarriottPHlscherC

Expected indication launch timelines for selected pipeline candidates Pharmaceutical companies are investing significantly in oral GLP-1s

Currently, no pure GIP agonist medications are approved for clinical use

The story of GLP-1 medicines has taken decades and begins with the venom of a lizard, and the regulation of blood sugar
